About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2014 (2014), Article ID 957013, 7 pages
http://dx.doi.org/10.1155/2014/957013
Clinical Study

Structured Self-Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie’s Disease

1Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK
2Sheffield Health and Social Care NHS Foundation Trust, Sheffield S11 9BF, UK

Received 5 July 2013; Revised 19 December 2013; Accepted 5 February 2014; Published 3 April 2014

Academic Editor: Darius J. Bagli

Copyright © 2014 Abas Kokab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Schwarzer, F. Sommer, T. Klotz, M. Braun, B. Reifenrath, and U. Engelmann, “The prevalence of Peyronie's disease: results of a large survey,” BJU International, vol. 88, no. 7, pp. 727–730, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. P. Mulhall, S. D. Creech, S. A. Boorjian et al., “Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening,” Journal of Urology, vol. 171, no. 6, pp. 2350–2353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. T. F. Lue, F. Giuliano, F. Montorsi et al., “Summary on the recommendations on sexual dysfunctions in men,” Journal of Sexual Medicine, vol. 1, no. 1, pp. 6–23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. F. Smith, W. O. Brant, V. Fradet et al., “Penile sonographic and clinical characteristics in men with Peyronie's disease,” Journal of Sexual Medicine, vol. 6, no. 10, pp. 2858–2867, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. F. Lue, “Peyronie's disease: an anatomically-based hypothesis and beyond,” International Journal of Impotence Research, vol. 14, no. 5, pp. 411–413, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Kadioglu, A. Tefekli, B. Erol, T. Oktar, M. Tunc, and S. Tellaloglu, “A retrospective review of 307 men with Peyronie's disease,” Journal of Urology, vol. 168, no. 3, pp. 1075–1079, 2002. View at Scopus
  7. L. A. Levine and J. M. Greenfield, “Establishing a standardized evaluation of the man with Peyronie's disease,” International Journal of Impotence Research, vol. 15, supplement 5, pp. S103–S112, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Kendirci, S. Nowfar, S. Gur, G. W. Jabren, S. C. Sikka, and W. J. G. Hellstrom, “The relationship between the type of penile abnormality and penile vascular status in patients with Peyronie's disease,” Journal of Urology, vol. 174, no. 2, pp. 632–635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. K. Gelbard, F. Dorey, and K. James, “The natural history of Peyronie's disease,” Journal of Urology, vol. 144, no. 6, pp. 1376–1379, 1990. View at Scopus
  10. U. Schwarzer, F. Sommer, T. Klotz, M. Braun, B. Reifenrath, and U. Engelmann, “The prevalence of Peyronie's disease: results of a large survey,” BJU International, vol. 88, no. 7, pp. 727–730, 2001.
  11. A. J. Bella, M. A. Perelman, W. O. Brant, and T. F. Lue, “Peyronie's disease (CME),” Journal of Sexual Medicine, vol. 4, no. 6, pp. 1527–1538, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Greenfield and L. A. Levine, “Peyronie's disease: etiology, epidemiology and medical treatment,” Urologic Clinics of North America, vol. 32, no. 4, pp. 469–478, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. G. H. Jordan, “Peyronie’s disease,” in Campell-Walsh Urology, A. J. Wein, L. R. Kavoussi, A. C. Novick, A. W. Partin, and C. A. Peters, Eds., pp. 818–838, Saunders Elsevier, Philadelphia, Pa, USA, 2007.
  14. J. P. Jarow and F. C. Lowe, “Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction,” Journal of Urology, vol. 158, no. 4, pp. 1388–1390, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. C. J. Devine Jr., K. D. Somers, G. H. Jordan, and S. M. Schlossberg, “Proposal: trauma as the cause of the Peyronie's lesion,” Journal of Urology, vol. 157, no. 1, pp. 285–290, 1997. View at Scopus
  16. R. B. Moreland and A. Nehra, “Pathophysiology of Peyronie's disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 406–410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. D. Bjekic, H. D. Vlajinac, S. B. Sipetic, and J. M. Marinkovic, “Risk factors for Peyronie's disease: a case-control study,” BJU International, vol. 97, no. 3, pp. 570–574, 2006.
  18. R. Almannie and S. Carrier, “Sexual dysfunction after surgical treatment of Peyronie's disease; Review article,” Sexologies, vol. 21, no. 2, pp. 48–54, 2012.
  19. W. J. G. Hellstrom, “Medical management of Peyronie's disease,” Journal of Andrology, vol. 30, no. 4, pp. 397–405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Primus, “Orgotein in the treatment of plastic induration of the penis (Peyronie's disease),” International Urology and Nephrology, vol. 25, no. 2, pp. 169–172, 1993. View at Scopus
  21. S. M. di Stasi, A. Giannantoni, G. Capelli et al., “Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease,” BJU International, vol. 91, no. 9, pp. 825–829, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. di Stasi, A. Giannantoni, R. L. Stephen et al., “A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease,” Journal of Urology, vol. 171, no. 4, pp. 1605–1608, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. E. W. Hauck, T. Diemer, H. U. Schmelz, and W. Weidner, “A critical analysis of nonsurgical treatment of Peyronie's disease,” European Urology, vol. 49, no. 6, pp. 987–997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Weidner, E. W. Hauck, and J. Schnitker, “Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study,” European Urology, vol. 47, no. 4, pp. 530–535, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Apaydin, B. Semerci, A. Kefi, N. Cikili, A. Gürsan, and N. Mülazimoglu, “The use of tamoxifen in the treatment of Peyronie’s disease,” International Journal of Impotence Research, vol. 10, supplement 57, 1998, abstract no. 421.
  26. C. Teloken, E. L. Rhoden, T. M. Grazziotin, C. T. da Ros, P. R. Sogari, and C. A. V. Souto, “Tamoxifen versus placebo in the treatment of Peyronie's disease,” Journal of Urology, vol. 162, no. 6, pp. 2003–2005, 1999. View at Scopus
  27. L. A. Mynderse and M. Monga, “Oral therapy for Peyronie's disease,” International Journal of Impotence Research, vol. 14, no. 5, pp. 340–344, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Safarinejad, “Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study,” International Journal of Impotence Research, vol. 16, no. 3, pp. 238–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. E. W. Hauck, H. U. Schmelz, T. Bschleipfer, and W. Weidner, “Conservative therapy of Peyronie’s disease,” in Peyronie's Disease, S. Lahme, Ed., pp. 55–62, Uni-Med, Bremen, Germany, 2005.
  30. E. W. Hauck, T. Bschleipfer, S. M. Haag, V. Rohde, and W. Weidner, “Assessment among German urologists of various conservative treatment modalities for Peyronie's disease. Results of a survey,” Urologe, vol. 44, no. 10, pp. 1189–1196, 2005 (German). View at Publisher · View at Google Scholar · View at Scopus
  31. R. B. Meacham, “Nonsurgical management of Peyronie's disease—are we making any progress?” Journal of Urology, vol. 176, no. 1, pp. 12–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. W. J. G. Hellstrom, M. Kendirci, R. Matern et al., “Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon α-2B for minimally invasive treatment for Peyronie's disease,” Journal of Urology, vol. 176, no. 1, pp. 394–398, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Greenfield, S. J. Shah, and L. A. Levine, “Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial,” Journal of Urology, vol. 177, no. 3, pp. 972–975, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. P. Mulhall, J. Schiff, and P. Guhring, “An analysis of the natural history of Peyronie's disease,” Journal of Urology, vol. 175, no. 6, pp. 2115–2118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Deveci, C. V. Hopps, K. O'Brien, M. Parker, P. Guhring, and J. P. Mulhall, “Defining the clinical characteristics of Peyronie's disease in young men,” Journal of Sexual Medicine, vol. 4, no. 2, pp. 485–490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. C. J. Nelson, C. Diblasio, M. Kendirci, W. Hellstrom, P. Guhring, and J. P. Mulhall, “The chronology of depression and distress in men with Peyronie's disease,” Journal of Sexual Medicine, vol. 5, no. 8, pp. 1985–1990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. C. Rosen, J. Henne, J. Catania, and S. E. lthof, “Patients-reported psychosocial impact of Peyronie's disease,” Journal of Sexual Medicine, vol. 5, p. 39, 2008.